Open-label, long-term follow-up of safety and biochemical disease control of Infacort in neonates, infants and children with congenital adrenal hyperplasia and adrenal insufficiency previously enrolled in the Infacort 003 study

Trial Profile

Open-label, long-term follow-up of safety and biochemical disease control of Infacort in neonates, infants and children with congenital adrenal hyperplasia and adrenal insufficiency previously enrolled in the Infacort 003 study

Recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Apr 2017

At a glance

  • Drugs Hydrocortisone (Primary)
  • Indications Adrenal insufficiency; Congenital adrenal hyperplasia
  • Focus Adverse reactions
  • Acronyms Infacort004
  • Sponsors Diurnal
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top